Newsroom | 1402 results

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that it will release its financial results for the quarter and year ended December 31, 2025 after the market close on Tuesday, March 3 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 3...

OAKLAND, Calif.--(BUSINESS WIRE)--CWCI's review of state data shows employer-reported COVID-19 illness cases led to huge fluctuations in California work injury and illness trends....

日本东京和大阪--(BUSINESS WIRE)--(美国商业资讯)-- Kirin Holdings Company, Limited (Kirin Holdings)和Immunosens Co., Ltd. (Immunosens)已启动一项独创“自检服务*1”的联合开发，旨在直观呈现人体的免疫状态。 Kirin Holdings通过KIRIN健康创新基金对Immunosens进行了投资*2。该基金是公司于2023年2月与日本领先的独立风险投资公司Global Brain Corporation共同设立的企业风险投资基金。双方一直在探索将Immunosens专有的POCT*3设备作为健康管理工具的应用潜力，以帮助消费者在疾病前期维持健康。 Kirin Holdings现已与Immunosens签订委托研究协议。通过结合Immunosens的专有技术，以及Kirin在全球首次发现*4的与浆细胞样树突状细胞(pDC)活性相关的尿液标志物，两家公司旨在开发一款简单而高精度的免疫功能可视化服务。 2025年5月公布的检测服务为邮寄式检测，可让个人定期监测自身免疫状态*5。与此不同，本次与...

日本東京和大阪--(BUSINESS WIRE)--(美國商業資訊)-- Kirin Holdings Company, Limited (Kirin Holdings)和Immunosens Co., Ltd. (Immunosens)已啟動一項獨創「自檢服務*1」的共同開發，旨在直覺式呈現人體的免疫狀態。 Kirin Holdings透過KIRIN健康創新基金對Immunosens進行了投資*2。該基金是公司於2023年2月與日本首屈一指的獨立創投公司Global Brain Corporation共同設立的企業創投基金。雙方一直在探索將Immunosens專有的POCT*3裝置做為健康管理工具的應用潛力，以協助消費者在疾病前期維持健康。 Kirin Holdings現已與Immunosens簽署委託研究協議。透過結合Immunosens的專有技術，以及Kirin在全球首次發現*4的與漿細胞樣樹突細胞(pDC)活性相關的尿液標記，兩家公司旨在開發一款簡單而又高精確度的免疫功能視覺化服務。 2025年5月公布的檢測服務為郵寄式檢測，可讓個人定期監測自身免疫狀態*5。與此不同，本次與I...

TOKYO & OSAKA, Japan--(BUSINESS WIRE)--Kirin Holdings Company, Limited (Kirin Holdings) and Immunosens Co., Ltd. (Immunosens) have begun the joint development of a unique “Self-Testing Service*1” designed to visualize a person’s immune status. Through the KIRIN HEALTH INNOVATION FUND, a corporate venture capital fund jointly established in February 2023 with Global Brain Corporation, one of Japan’s leading independent venture capital firms, Kirin Holdings invested in Immunosens*2 and has been e...

EL SEGUNDO, Calif.--(BUSINESS WIRE)--A federal court ruled MetLife wrongly denied long-term disability benefits, setting a key precedent for long-haul COVID ERISA claims....

BIRMINGHAM, Ala.--(BUSINESS WIRE)--Southern Research and London-based Pathogenus Consulting have signed a three-year partnership that will allow both organizations to capitalize on growing research opportunities around the world. "We’ve seen clear momentum in our work with partners outside the United States, especially with Japan and European pharmaceutical companies, and the opportunity to broaden that footprint is both exciting and timely,” said Fusataka Koide, senior director of global clien...

NEW YORK--(BUSINESS WIRE)--PFE Q4 2025 Earnings Release...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, on Monday, January 12, 2026, at 5:15 p.m. Pacific Time. About Arcturus Found...